Filtered By:
Drug: Aspirin
Therapy: Statin Therapy

This page shows you your search results in order of relevance.

Order by Relevance | Date

Total 230 results found since Jan 2013.

C-Reactive Protein as a Prognostic Marker After Lacunar Stroke: Levels of Inflammatory Markers in the Treatment of Stroke Study Clinical Sciences
Conclusions— Among recent lacunar stroke patients, hsCRP levels predict the risk of recurrent strokes and other vascular events. hsCRP did not predict the response to dual antiplatelets. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00059306.
Source: Stroke - February 24, 2014 Category: Neurology Authors: Elkind, M. S. V., Luna, J. M., McClure, L. A., Zhang, Y., Coffey, C. S., Roldan, A., Del Brutto, O. H., Pretell, E. J., Pettigrew, L. C., Meyer, B. C., Tapia, J., White, C., Benavente, O. R., on behalf of the LIMITS Investigators, The LIMITS Investigators Tags: Cerebrovascular disease/stroke, Cerebral Lacunes, Epidemiology Clinical Sciences Source Type: research

One-Year Outcomes After Minor Stroke or High-Risk Transient Ischemic Attack Clinical Sciences
Conclusions—Contemporary secondary stroke prevention strategies based on thorough diagnostic evaluation may contribute to the low subsequent vascular event rates observed in real-world clinical practice in Korea.
Source: Stroke - October 23, 2017 Category: Neurology Authors: Hong-Kyun Park, Beom Joon Kim, Moon-Ku Han, Jong-Moo Park, Kyusik Kang, Soo Joo Lee, Jae Guk Kim, Jae-Kwan Cha, Dae-Hyun Kim, Hyun-Wook Nah, Tai Hwan Park, Sang-Soon Park, Kyung Bok Lee, Jun Lee, Keun-Sik Hong, Yong-Jin Cho, Byung-Chul Lee, Kyung-Ho Yu, M Tags: Quality and Outcomes, Ischemic Stroke, Transient Ischemic Attack (TIA) Original Contributions Source Type: research

Statins and the Risk of Intracerebral Hemorrhage in Patients With Previous Ischemic Stroke or Transient Ischemic Attack Clinical Sciences
Conclusions—Statin use was not associated with an increased risk of ICH among patients with a previous history of IS/TIA.
Source: Stroke - November 27, 2017 Category: Neurology Authors: David Gaist, Larry B. Goldstein, Lucia Cea Soriano, Luis Alberto Garcia Rodriguez Tags: Secondary Prevention, Cerebrovascular Disease/Stroke, Intracranial Hemorrhage, Ischemic Stroke, Transient Ischemic Attack (TIA) Original Contributions Source Type: research

Incidence, Trends, and Predictors of Ischemic Stroke 1 Year After an Acute Myocardial Infarction Clinical Sciences
Conclusions— The risk of ischemic stroke within a year after myocardial infarction is substantial but has clearly been reduced during the studied time period. The major predictive factors found to correlate well with previous investigations. Reperfusion treatment, thrombocyte aggregation inhibition, and lipid lowering are the main contributors to the observed risk reduction.
Source: Stroke - October 27, 2014 Category: Neurology Authors: Ulvenstam, A., Kajermo, U., Modica, A., Jernberg, T., Soderstrom, L., Mooe, T. Tags: Platelet function inhibitors, Acute myocardial infarction, Acute Cerebral Infarction, Platelets Clinical Sciences Source Type: research

FDA strengthens warning that NSAIDs increase heart attack and stroke risk
Back in 2005, the FDA warned that taking nonsteroidal anti-inflammatory drugs (NSAIDs) like ibuprofen and naproxen increased the risk of having a heart attack or stroke. Last week it took the unusual step of further strengthening this warning. This was done on the advice of an expert panel that reviewed new information about NSAIDs and their risks. Because NSAIDs are widely used, it’s important to be aware of downsides of taking an NSAID and to take steps to limit the risk. Many people take NSAIDs to relieve mild to moderate pain. These medications may be particularly effective in conditions in which pain results pri...
Source: New Harvard Health Information - July 13, 2015 Category: Consumer Health News Authors: Gregory Curfman, MD Tags: Heart Health heart attack heart disease NSAIDS Stroke Source Type: news

Recurrent stroke in a patient with vitamin B12 deficiency and MTHFR mutation
We report an unusual case of recurrent stroke in a patient with vitamin B12 deficiency who was also homozygous for the methylene tetrahydrofolate reductase (MTHFR) gene mutation. The patient was a 35-year-old male vegetarian with no known medical history who initially presented with global aphasia, slurred speech, right facial weakness, and right-sided hemiplegia and was found to have a stroke (NIH Stroke Scale score of 25). At that time a CT scan of the head ruled out intracranial hemorrhage and a CT angiogram of the head and neck was done. The patient was found to have occlusion of the M1 segment of the left middle cereb...
Source: Neurology Clinical Practice - February 12, 2017 Category: Neurology Authors: Zacharia, G., Shani, D., Ortiz, R. A. Tags: Stroke in young adults, Stroke prevention, Hematologic, All Cerebrovascular disease/Stroke Case Source Type: research

Recurrent cryptogenic stroke in young adult linked to congenital left ventricular diverticulum
A 47-year-old man had an acute ischemic stroke (IS); brain MRI revealed multiple silent old IS (figure 1A). A comprehensive workup, including prolonged cardiac monitoring (cumulated duration of 25 days) and cardiac transthoracic/transesophageal echography, was negative. Eleven months later, despite statin and aspirin therapy, a new symptomatic embolic IS of undetermined source occurred (figure 1B). Cardiac MRI1 revealed a left apical dyskinetic saccular evagination (figure 2, A–C) consistent with a congenital left ventricular diverticulum confirmed on left ventriculography (figure 2D) and the presumed source of recur...
Source: Neurology - November 13, 2016 Category: Neurology Authors: Gaillard, N., Targosz, F., Bertrand, J. L., Sablot, D., Bensalah, Z. M. Tags: Stroke in young adults, Cardiac, Embolism, Infarction NEUROIMAGES Source Type: research

Statins in stroke prevention: present and future.
CONCLUSION: Traditionally, there has been no clear data demonstrating that adding other lipid-modifying drugs to statins results in a further decrease in stroke or other cardiovascular event, but now things have changed and future directions include combinations with ezetimibe and new treatments such as PCSK9 inhibitors. Only time will tell the real roll of these new promising non-statin lipid-modifying therapies on stroke prevention. PMID: 27160755 [PubMed - as supplied by publisher]
Source: Current Pharmaceutical Design - May 9, 2016 Category: Drugs & Pharmacology Authors: Castilla-Guerra L, Del Carmen Fernandez-Moreno M, Colmenero-Camacho MA Tags: Curr Pharm Des Source Type: research

Opportunities for intervention: stroke treatments, disability and mortality in urban Tanzania
ConclusionsThe 90-day mortality of stroke presenting at MNH is 50%, much higher than in higher income settings. Although severe stroke presentations are a major factor, efforts to improve the quality of care and prevent complications of stroke are urgently needed. Acute stroke interventions with low number needed to treat represent challenging long-term goals.
Source: International Journal for Quality in Health Care - August 28, 2018 Category: International Medicine & Public Health Source Type: research

A Combination of Atorvastatin and Aspirin Enhances the Pro-Regenerative Interactions of Marrow Stromal Cells and Stroke-Derived Monocytes In Vitro
Conclusion: Atorvastatin, alone and in combination with aspirin can promote anti-inflammatory effect by modulating the secretome profile of Mo and MSCs. Our results suggest that stroke trials involving the use of intravenous MSCs should consider the effect of aspirin and atorvastatin, both of which are administered to the majority of hospitalized ischemic stroke patients.
Source: Frontiers in Pharmacology - April 20, 2021 Category: Drugs & Pharmacology Source Type: research

Long-Term Effects of Secondary Prevention on Cognitive Function in Stroke Patients.
CONCLUSIONS: Appropriate vascular risk management was associated with a long-term reduced risk of cognitive impairment. Focus on optimal preventive drug therapy of vascular risk factors and management should be supported. PMID: 23935013 [PubMed - as supplied by publisher]
Source: Circulation - August 9, 2013 Category: Cardiology Authors: Douiri A, McKevitt C, Emmett ES, Rudd AG, Wolfe CD Tags: Circulation Source Type: research

A high burden of ischemic stroke in regions of Eastern/Central Europe is largely due to modifiable risk factors.
Abstract Incidence and mortality of ischemic stroke in Croatia is significantly higher than in many other developed European countries. Here, we aimed to evaluate underlying conditions of this unacceptably high ischemic stroke burden. An observational prospective cohort study of ) first-ever ischemic stroke patients identified in a population-based incidence study (N=751) (study 1, S1) and a concurrent case-control trial (215 patients, 125 controls, S2) were conducted in the country of Varazdin from 2007-2010. Atrial fibrillation (AF) was common (36.1% in S1, 40.9% in S2) and mostly (>50%) unrecognized before t...
Source: Current Neurovascular Research - July 30, 2015 Category: Neurology Authors: Pikija S, Trkulja V, Malojcic B, Mutzenbach JS, Sellner J Tags: Curr Neurovasc Res Source Type: research

Stroke subtypes and interventional studies for transient ischemic attack.
Authors: Lavallée P, Amarenco P Abstract Transient ischemic attack (TIA) is the most important risk factor for ischemic stroke. The risk is the highest in the first hours after symptom onset, and treatment must be initiated in emergency. In the acute phase, antithrombotic agent is probably the most important treatment, but it is not excluded that lipid-lowering agents and/or antihypertensive drugs are also important. For current guidelines, monotherapy of antiplatelet agent remains the gold standard in emergency. However, most recent data and meta-analysis support a combination therapy of clopidogrel and aspirin. ...
Source: Frontiers of Neurology and Neuroscience - December 2, 2015 Category: Neuroscience Tags: Front Neurol Neurosci Source Type: research

Edaravone offers neuroprotection for acute diabetic stroke patients
ConclusionEdaravone represents a promising neuroprotectant against cerebral ischemic injury in diabetic patients.
Source: Irish Journal of Medical Science - October 31, 2016 Category: Journals (General) Source Type: research

Temporal Trends and Patient Characteristics Associated With Drug Utilisation After First-Ever Stroke: Insights From Chronic Disease Registry Data in Singapore.
CONCLUSION: This study reveals changes in prescription behaviour over time in a multiethnic Asian population with first-ever stroke. Patient characteristics including younger age, Malay ethnicity and certain comorbidities (i.e. hyperlipidaemia, atrial fibrillation) were associated with the combined use of all 3 guideline medications among ischaemic stroke patients. PMID: 32301477 [PubMed - in process]
Source: Ann Acad Med Singapo... - February 29, 2020 Category: General Medicine Authors: Yeo SH, Toh MPH, Lee SH, Seet RC, Wong LY, Yau WP Tags: Ann Acad Med Singapore Source Type: research